Aehr Test Systems vs Novartis AG — how do they compare? Aehr Test Systems trades at $122 (market cap $3.82B), while Novartis AG trades at $152.38 (market cap $295.37B). The key difference: Novartis AG is far larger — about 77.3× Aehr Test Systems's market cap, and Novartis AG pays a 3.07% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.
| AEHR | NVS | |
|---|---|---|
Market Cap | $3.82B | $295.37B |
Sector | Technology | Health |
52-Week High | $117.18 | $168.62 |
52-Week Low | $17.38 | $119.31 |
Enterprise Value | $3.72B | $336.69B |
Dividend Yield | — | 3.07% |
Trailing returns across standard periods
Latest headlines on both assets
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →